Skye Bioscience Receives FDA Authorization of Investigational New Drug Application for SBI-100 OE
December 20, 2022
Phase 2 clinical trial planned to start in H1 2023San Diego, California, December 20, 2022 — Skye Bioscience, Inc. (OTCQB: SKYE) (“Skye” or the “Company”), a pharmaceutical company developing a proprietary, synthetic cannabinoid derivative to treat glaucoma, today announced that the U.S. Food and Drug Administration (“FDA”) has given... Read more
Ryan Allway December 30th, 2021 U.S. FDA granted JZP150 Fast Track designation in PTSD, underscoring the unmet needs of patients If approved, JZP150 would become the first new drug approved in 20 years for patients with PTSD; topline data readout anticipated by the end of 2023 DUBLIN, Dec. 30, 2021 /PRNewswire/... Read more
